يعرض 101 - 120 نتائج من 14,322 نتيجة بحث عن '(((( c largest decrease ) OR ( ((b large) OR (a large)) decrease ))) OR ( ae rate increased ))*', وقت الاستعلام: 1.02s تنقيح النتائج
  1. 101

    Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx حسب Dewan Zhao (21547445)

    منشور في 2025
    "…Introduction<p>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. …"
  2. 102

    Effect of AES. حسب David Samuel Bhatti (17846822)

    منشور في 2024
    "…This research implements instant messaging, voice conversation, and secret key generation over DH while implementing and observing the role of multi-threading in multiqueue systems that serve incoming calls. By increasing the number of threads from one to two, the SIP response time improved from 20.23809 to 0.08070 min at an arrival rate of 4250 calls/day and a service rate of three calls/min. …"
  3. 103
  4. 104

    Image_1_Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis.tif حسب Yangyang Wang (642852)

    منشور في 2023
    "…In a subgroup analysis concerning 3-4 grade AEs revealed R-COMP was associated with a decrease in grade III/IV neutropenia and cardiac toxic events; RminiCEOP was associated with the lower rates of 3-4 grade anemia, thrombocytopenia and infection; RCHOP21 had the lowest rate of 3-4 grade AE of neurotoxicity.…"
  5. 105

    Table_1_Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis.docx حسب Yangyang Wang (642852)

    منشور في 2023
    "…In a subgroup analysis concerning 3-4 grade AEs revealed R-COMP was associated with a decrease in grade III/IV neutropenia and cardiac toxic events; RminiCEOP was associated with the lower rates of 3-4 grade anemia, thrombocytopenia and infection; RCHOP21 had the lowest rate of 3-4 grade AE of neurotoxicity.…"
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113

    Supplementary Material for: Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease حسب Fabbrocini G. (7463126)

    منشور في 2021
    "…<b><i>Objective:</i></b> To evaluate how the burden of HS disease impacts on patient well-being and working activities in a large Italian population over a period of 9 months. …"
  14. 114
  15. 115

    A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas حسب L. E. van der Meeren (7490675)

    منشور في 2019
    "…<div><p>Diffuse large B-cell lymphoma—not otherwise specified (DLBCL-NOS) is a large and heterogeneous subgroup of non-Hodgkin lymphoma. …"
  16. 116

    Table_2_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf حسب Tianqi Xu (9574329)

    منشور في 2021
    "…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …"
  17. 117

    Table_1_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf حسب Tianqi Xu (9574329)

    منشور في 2021
    "…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …"
  18. 118

    Prognostic value of lactate dehydrogenase, serum albumin and the lactate dehydrogenase/albumin ratio in patients with diffuse large B-cell lymphoma حسب Wenke Wu (17665962)

    منشور في 2023
    "…<p>To investigate the prognostic value of lactate dehydrogenase (LDH), serum albumin (ALB) and the lactate dehydrogenase/albumin ratio (LAR) in diffuse large B-cell lymphoma (DLBCL) before primary treatment.…"
  19. 119
  20. 120